Skip to main content

Volume 16, Issue 11, November 2019 - First Report Managed Care

Featured Article

11/20/2019
As the push to deliver increasingly higher quality care at lower costs continues to be of the utmost importance, stakeholders and providers are implementing and testing a number of models to see what suits their patient population best.
As the push to deliver increasingly higher quality care at lower costs continues to be of the utmost importance, stakeholders and providers are implementing and testing a number of models to see what suits their patient population best.
As the push to deliver...
11/20/2019
First Report Managed Care
11/20/2019
In the wake of the recent massive out-of-court settlement by a maker and three distributors of opioids, experts weigh in on the role managed care stakeholders should play at this critical juncture.
In the wake of the recent massive out-of-court settlement by a maker and three distributors of opioids, experts weigh in on the role managed care stakeholders should play at this critical juncture.
In the wake of the recent...
11/20/2019
First Report Managed Care
11/20/2019
A recent analysis estimates current levels of wasteful spending in the US health care system and suggests there are opportunities to intervene and save. Experts point to shared decision-making as one tool that could help address waste factors...
A recent analysis estimates current levels of wasteful spending in the US health care system and suggests there are opportunities to intervene and save. Experts point to shared decision-making as one tool that could help address waste factors...
A recent analysis estimates...
11/20/2019
First Report Managed Care

Department

Conference Insider
11/20/2019
Statin use is associated with a 43% lower risk of hepatocellular carcinoma (HCC), according to new study results presented at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting and Postgraduate Course.
Statin use is associated with a 43% lower risk of hepatocellular carcinoma (HCC), according to new study results presented at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting and Postgraduate Course.
Statin use is associated with a...
11/20/2019
First Report Managed Care
Conference Insider
11/20/2019
AK002—an anti-SIGLEC8 antibody—may be a safe and effective treatment option in eosinophilic gastritis (EG) and eosinophilic gastroenteritis (EGE), according to results of ENIGMA, a phase 2 clinical trial.
AK002—an anti-SIGLEC8 antibody—may be a safe and effective treatment option in eosinophilic gastritis (EG) and eosinophilic gastroenteritis (EGE), according to results of ENIGMA, a phase 2 clinical trial.
AK002—an anti-SIGLEC8...
11/20/2019
First Report Managed Care
Conference Insider
11/20/2019
Gastroenterology patients with avoidant/restrictive food intake disorder (ARFID) are less likely to be taking psychotropic medications, have less-severe body image concerns, and are frustrated with being unable to eat what they want compared...
Gastroenterology patients with avoidant/restrictive food intake disorder (ARFID) are less likely to be taking psychotropic medications, have less-severe body image concerns, and are frustrated with being unable to eat what they want compared...
Gastroenterology patients with...
11/20/2019
First Report Managed Care
Conference Insider
11/20/2019
Budesonide oral suspension (BOS) appears to be a safe and effective induction therapy for eosinophilic esophagitis (EoE) among adolescents and adults, according to results of a phase 3 clinical trial that were presented at the ACG 2019 Annual...
Budesonide oral suspension (BOS) appears to be a safe and effective induction therapy for eosinophilic esophagitis (EoE) among adolescents and adults, according to results of a phase 3 clinical trial that were presented at the ACG 2019 Annual...
Budesonide oral suspension (BOS)...
11/20/2019
First Report Managed Care
Conference Insider
11/20/2019
Using a fluoroscopy system enabled with artificial intelligence (AI) during image-guided endoscopy can significantly reduce patients’ exposure to radiation and diminish the scatter effect to endoscopy personnel, according to late-breaking...
Using a fluoroscopy system enabled with artificial intelligence (AI) during image-guided endoscopy can significantly reduce patients’ exposure to radiation and diminish the scatter effect to endoscopy personnel, according to late-breaking...
Using a fluoroscopy system...
11/20/2019
First Report Managed Care
Conference Insider
11/20/2019
Nancy Myers, PhD, vice president at the American Hospital Association Center for Health Innovation, and James Dom Dera, MD, FAAFP, population health medical director at NewHealth Collaborative/Summa Health, discussed care coordination in the...
Nancy Myers, PhD, vice president at the American Hospital Association Center for Health Innovation, and James Dom Dera, MD, FAAFP, population health medical director at NewHealth Collaborative/Summa Health, discussed care coordination in the...
Nancy Myers, PhD, vice president...
11/20/2019
First Report Managed Care

News

Conference Insider
11/20/2019
AK002—an anti-SIGLEC8 antibody—may be a safe and effective treatment option in eosinophilic gastritis (EG) and eosinophilic gastroenteritis (EGE), according to results of ENIGMA, a phase 2 clinical trial.
AK002—an anti-SIGLEC8 antibody—may be a safe and effective treatment option in eosinophilic gastritis (EG) and eosinophilic gastroenteritis (EGE), according to results of ENIGMA, a phase 2 clinical trial.
AK002—an anti-SIGLEC8...
11/20/2019
First Report Managed Care
Conference Insider
11/20/2019
Budesonide oral suspension (BOS) appears to be a safe and effective induction therapy for eosinophilic esophagitis (EoE) among adolescents and adults, according to results of a phase 3 clinical trial that were presented at the ACG 2019 Annual...
Budesonide oral suspension (BOS) appears to be a safe and effective induction therapy for eosinophilic esophagitis (EoE) among adolescents and adults, according to results of a phase 3 clinical trial that were presented at the ACG 2019 Annual...
Budesonide oral suspension (BOS)...
11/20/2019
First Report Managed Care